Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Relatlimab (Primary) ; Zanzalintinib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STELLAR-002
  • Sponsors Exelixis

Most Recent Events

  • 22 May 2025 Results presented in the Exelixis Media Release.
  • 22 May 2025 According to an Exelixis media release, results from an expansion cohort of the phase 1b/2 STELLAR-002 trial, as well as data from multiple dose-escalation cohorts, evaluating zanzalintinib in combination with either nivolumab (Opdivo) or a fixed-dose combination of nivolumab and relatlimab (Opdualag) in previously untreated advanced clear cell renal cell carcinoma (RCC), will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 02 Apr 2025 Planned End Date changed from 1 May 2026 to 28 Jun 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top